Polypeptides
US12173054B2 · kind B2 · utility
0Cited by
12References
16Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Nov 17, 2020 |
| Grant date | Dec 24, 2024 |
| Priority date | — |
| Expiry date | Jul 10, 2042 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
Described herein is a polypeptide comprising an immunoglobulin chain variable domain comprising three complementarity determining regions (CDR1-CDR3) and four framework regions, wherein: (a) at least one lysine residue in CDR1, CDR2 and/or CDR3 has been substituted with at least one histidine residue, and/or (b) at least one arginine residue in CDR1, CDR2 and/or CDR3 has been substituted with at least one histidine residue. The polypeptides of this disclosure possess increased intestinal stability relative to a corresponding polypeptide not having the histidine substitutions.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.